Clinical Trial Update: Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of the BioMed rTSST-1 variant vaccine in healthy adults has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Toxic Shock Syndrome

Drugs mentioned

• rTSST-1 Variant Vaccine (rTSST-1 variant vaccine)

Snippet

Sponsor: Biomedizinische Forschungs gmbH | Conditions: Toxic Shock Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-12-13